TGFBIp expression adds prognostic information in an ovarian-cancer ML study
Source check: Source checked. Not independent scientific confirmation.
Finding: In a retrospective tissue-microarray cohort of 155 epithelial ovarian-cancer patients, support vector machine and random forest models combined clinicopathological features with tumor and stromal TGFBIp expression. Adding both expression compartments improved held-out vital-status discrimination by a reported AUC difference of 0.038 (95% CI 0.002–0.092). Validation was internal, follow-up duration varied, and binary endpoints did not model event timing or censoring. Recurrence specificity and calibration were limited, and clinical utility remains unproven.
Technology: Support vector machine; random forest
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Twelve algorithms compared across four expression-inclusion strategies; preprocessing/tuning/model selection limited to training data, 155-patient retrospective cohort and held-out final evaluation. Specific biomarker incremental-value result, not a clinical-benefit claim.
- Test and result
- Internal held-out prediction and paired-bootstrap incremental-value comparison.
- Limitation / still unknown
- External validation, time-to-event performance, treatment confounding and clinical benefit remain unestablished.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC13749431/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 21 Nov 2026. Review scope: Primary full article Methods, Results and limitations plus Europe PMC bibliographic metadata; PMC full article..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.